Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer

NCT00065429 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: BB-10901

Sponsor

ImmunoGen, Inc.